HDinHD: Open Source Science for the HD Research Community
The goal of HDinHD is to foster and support a collaborative community united in its drive to accelerate the development of therapeutics that will delay the onset and/or ameliorate the effects of Huntington’s disease. HDinHD seeks to achieve this through:
- Sharing HD-related primary scientific data
- Sharing analyses and computational models built from HD-related scientific data
- Providing browsing and data interrogation tools over both primary and analyzed data that facilitate data exploration and hypothesis generation
- Building a forum for HD researchers to highlight their data, tools, know-how and insight to the community
The HDinHD website is currently a joint development effort by CHDI and UCLA, through the laboratory of Dr. Giovanni Coppola. As you will see when you Register for access, HDinHD highlights data and tools provided by the broader community. If you are interested in Contributing Data to HDinHD, suggest links to other HD-related scientific data or websites, or would otherwise like to provide Feedback to us, we encourage you to do so. HDinHD is for the community; please help us tailor and grow HDinHD in a direction that can make a difference to your research, and ultimately, to improve the lives of HD families.
Want to learn more about HDinHD?
Watch a detailed video overview of HDinHD presented at the 16th Annual HD Therapeutics Conference (April 2021). The video outlines data resources and tools within HDinHD and provides a detailed demonstration of the new HD Explorer tool. |
Read the following publication introducing HDinHD: HDinHD: A Rich Data Portal for Huntington’s Disease Research, J Huntingtons Dis., 10, 405-412
Latest news and publications from around the HD Ecosystem
HDBuzz
- Beta-blockers associated with delayed onset and decreased progression of Huntington’s disease
- Moving into the Fast Lane: uniQure and the FDA Are on the Same Track for Accelerated Approval
- Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
- Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals
- Giving Thanks to the Huntington's Disease Family Community for Advancing Research
Literature
- Recent advances in stem cell therapy: efficacy, ethics, safety concerns, and future directions focusing on neurodegenerative disorders - a review
- Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors
- Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators
- Hijacking intercellular trafficking for the spread of protein aggregates in neurodegenerative diseases: a focus on tunneling nanotubes (TNTs)
- Docosahexaenoic Acid (DHA) Supplementation in a Triglyceride Form Prevents from Polyglutamine-Induced Dysfunctions in <em>Caenorhabditis elegans</em>
News
- What is wrong with Denny in Virgin River? Character explored - Soap Central
- The secret life of ALAS1: How a basic science discovery could pave the way for better siRNA ...
- Neurocrine says Crenessity now available in U.S. | Markets Insider
- A tropical disease in Switzerland: Call for coordinated action on Chagas disease
- Bob Dylan film 'A Complete Unknown': Timothée Chalamet, Edward Norton spoke about being ...